TAMPA, Fla.--(BUSINESS WIRE)--Xcelience, a leader in early drug development, has expanded its solid oral dosage form development and manufacturing capabilities to include a Vector TFC-220 Roller Compactor in the GMP Manufacturing area. The addition of this new equipment enables clients to achieve a faster transition from development in the experimental area to GMP production of clinical supplies.
Dry granulation technology represents an important option for clients faced with development challenges resulting from moisture sensitive active pharmaceutical ingredients (APIs). Xcelience currently maintains a Vector TFC-Lab Micro Roller Compactor in the experimental area. The TFC-220 is a natural transition for scale-up to the GMP Manufacturing area and significantly expands our processing capacity for dry granulation. The TFC-220 is capable of processing blends at a rate of up to 20 kg/hour.
"Taking a cross-functional approach to dry granulation ensures effective technical transfer and supports improved manufacturing outcomes," says Ted Koontz, Director of Operations.
Xcelience is a contract research organization providing formulation development, preformulation, analytical, and clinical trial manufacturing to a global client base since 1997. The company is renowned for reliably expediting early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab. For more detailed information about Xcelience, visit www.xcelience.com.